Saturday 17 October 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
17.06
0.73
−4.10%
Follow SRPT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 6 | 4 |
| (21.37%) | (53.47%) | 4.91% | (9.48%) | ||
| (7.66%) | (19.51%) | 1.96% | (3.98%) | ||
ROIC |
(5.26%) | (42.46%) | (1.51%) | (5.64%) | |
Return on Tangible Assets |
(12.57%) | (39.90%) | 3.03% | (6.68%) | |
Average Days of Receivables |
59.84 | 66.12 | 65.98 | 69.66 | |
Free Cash Flow per Share |
(3.88) | (3.15) | 1.03 | 0.71 | |
Free Cash Flow |
(388.84) | (315.33) | 108.24 | 74.97 | |
Capital Expenditures |
(144.20) | (109.85) | (67.04) | (36.04) | |
| Other line items | |||||
Cash ROIC |
(12.13%) | (10.84%) | 3.61% | 2.37% | |
Accounts Receivable Turnover |
5.81 | 4.40 | 4.14 | 4.37 | |
Accounts Payable Turnover |
5.39 | 3.39 | 7.16 | 8.61 | |
Inventory Turnover |
0.70 | 1.01 | 0.83 | 0.85 | |
Average Days of Payables |
59.87 | 122.09 | 31.68 | 23.04 | |
Days of Inventory on Hand |
685.91 | 397.67 | 450.67 | 408.67 | |
Tax Rate |
0.08 | 0.02 | 1.66 | 0.04 | |
Research and Development Expense of Revenue |
57.86% | 69.24% | 41.32% | 39.99% | |
Selling, General and Administrative Expense of Revenue |
21.85% | 22.37% | 21.38% | 22.12% | |
Share Based Compensation of Revenue |
5.93% | 5.61% | 5.10% | 5.00% | |
Operating CF/Net income |
0.90 | 0.29 | 2.69 | (0.81) | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.12 | 0.13 | |
Capex/Depreciation |
(3.79) | (2.80) | (1.63) | (0.86) | |
Revenue per Share |
24.08 | 21.96 | 20.80 | 18.73 | |
Operating CF per Share |
(2.44) | (2.05) | 1.67 | 1.05 | |
Capex per Share |
(1.44) | (1.10) | (0.64) | (0.34) | |
Capex to Sales |
0.06 | 0.05 | 0.03 | 0.02 |
Columns are period end dates